Ipsen • Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics,Brussel
Location - Ipsen
احصائيات اساسية Ipsen
قيمة المبيعات
Activities - Ipsen
Main activities within the Kompass classification
Secondary activities within the Kompass classification
التصنيفات الأخرى لدول أخرى
NACE-BEL (BE 2025) : Manufacture of medicaments (21201)
NACE Rev.2.1 (EU 2025) : Manufacture of pharmaceutical preparations (2120)
NACE-BEL (BE 2008) : Manufacture of medicines (21201)
NACE Rev.2 (EU 2008) : Manufacture of pharmaceutical preparations (2120)
ISIC 4 (WORLD) : Manufacture of pharmaceuticals, medicinal chemical and botanical products (2100)
Follow us - Ipsen
| Discover more on our Website |
|---|
Kompass membership
| Kompass ID? | BE0029421 |
|---|
Legal information - Ipsen
| Type | المكتب الرئيسي |
|---|---|
| Year established | 1982 |
| Legal form | NV/SA/AG |
| Activity (BEL25) | Manufacture of medicaments (21201) |
| Registration No. | 2020493469 |
| Registration No. | 0422650477 |
| VAT no |
BE0422650477 |
| No employees | من 20 الى 49 Employees |
معلومات عامة Ipsen
| Import area |
|
|---|
Other Companies recommended by Kompass:
Looking for new B2B Leads ?
Purchase a Company list with the executives and contact details
You might also like:
Need help finding the right information ? Let us guide you to the best solutions !
I am looking for :
The shortest path to your future customers and suppliers
"I would recommend EasyBusiness to all sales teams."
Test EasyBusiness for 14 days for free
No payment or credit card required
All-in-one prospecting solution designed to improve your productivity
Find your next customer today! Your shortcut to faster, more targeted and successful lead generation
Register for free and turn reliable data into real business opportunities
Your data is used to recontact you or send you communications and may be processed by Kompass, for the purposes of legitimate interest (Article 6 1.f of the GDPR).
You may object to its processing by email: dpo@kompass.com.
Find out more: see our privacy policy.